Kymera Therapeutics (NASDAQ:KYMR) Director Bruce Booth Sells 3,135 Shares

Key Points

• Director Bruce Booth sold 3,135 shares on April 15 at an average price of $90.10 (≈$282,464) under a pre‑arranged Rule 10b5‑1 plan; he still directly owns 674,956 shares (~$60.8M) and has completed earlier sizable sales, including 81,866 shares on March 2.
• Kymera missed Q4 expectations with EPS of ($0.97) vs. ($0.77) expected and revenue of $2.87M vs. $14.8M expected (revenue down 60.8% YoY); the stock trades near $86.14 and carries a "Moderate Buy" analyst consensus with an average target of $118.90.

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) Director Bruce Booth sold 3,135 shares of the business's stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $90.10, for a total transaction of $282,463.50. Following the completion of the transaction, the director directly owned 674,956 shares of the company's stock, valued at $60,813,535.60. This trade represents a 0.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bruce Booth also recently made the following trade(s):

• On Wednesday, April 15th, Bruce Booth sold 2,200 shares of Kymera Therapeutics stock. The shares were sold at an average price of $89.95, for a total transaction of $197,890.00.
• On Tuesday, April 14th, Bruce Booth sold 4,159 shares of Kymera Therapeutics stock. The stock was sold at an average price of $89.97, for a total transaction of $374,185.23.
• On Monday, March 2nd, Bruce Booth sold 81,866 shares of Kymera Therapeutics stock. The stock was sold at an average price of $90.13, for a total transaction of $7,378,582.58.

Kymera Therapeutics Stock Performance

NASDAQ:KYMR traded down $2.86 during midday trading on Thursday, reaching $86.14. 554,950 shares of the stock traded hands, compared to its average volume of 732,626. The stock has a market capitalization of $7.03 billion, a PE ratio of -23.41 and a beta of 2.28. Kymera Therapeutics, Inc. has a 12-month low of $24.72 and a 12-month high of $103.00. The business has a 50-day moving average of $83.69 and a two-hundred day moving average of $74.15.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by ($0.20). The firm had revenue of $2.87 million during the quarter, compared to analysts' expectations of $14.80 million. Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.Kymera Therapeutics's revenue for the quarter was down 60.8% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.88) earnings per share. Research analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Hedge Funds Weigh In On Kymera Therapeutics

A number of large investors have recently bought and sold shares of the business. Baker BROS. Advisors LP boosted its position in Kymera Therapeutics by 30.2% during the fourth quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company's stock worth $673,620,000 after purchasing an additional 2,005,813 shares in the last quarter. Avoro Capital Advisors LLC raised its stake in shares of Kymera Therapeutics by 17.7% during the 4th quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company's stock worth $581,610,000 after buying an additional 1,124,747 shares during the period. Vanguard Group Inc. raised its stake in shares of Kymera Therapeutics by 15.6% during the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company's stock worth $487,685,000 after buying an additional 845,922 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in Kymera Therapeutics by 20.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company's stock valued at $479,258,000 after purchasing an additional 1,061,957 shares in the last quarter. Finally, State Street Corp boosted its holdings in Kymera Therapeutics by 9.4% in the 4th quarter. State Street Corp now owns 2,209,837 shares of the company's stock worth $171,947,000 after buying an additional 190,383 shares during the last quarter.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Citigroup increased their price objective on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the company a "buy" rating in a research report on Monday, March 2nd. Wall Street Zen lowered Kymera Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, March 7th. Barclays raised their price objective on Kymera Therapeutics to $133.00 and gave the stock an "overweight" rating in a research note on Tuesday, January 27th. Stephens lifted their target price on Kymera Therapeutics from $95.00 to $100.00 and gave the stock an "overweight" rating in a report on Monday, March 2nd. Finally, UBS Group upped their target price on Kymera Therapeutics from $90.00 to $128.00 and gave the company a "buy" rating in a research report on Tuesday, March 3rd. One research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $118.90.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company's pipeline emphasizes immunology and oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.